AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 37166786 — intervention group
Group type: COMPARATOR
Intervention: Stromal hydration
Number of subjects: 126
Study 37166798 — intervention group
Group type: EXPERIMENTAL
Intervention: Diffusing alpha-emitter radiation therapy (DaRT) with a physical dose of 10 Gy (equivalent weighted dose of 200 CGE) to the tumor.
Number of subjects: 10
Study 37166798 — intervention group
Group type: EXPERIMENTAL
Intervention: DaRT procedure
Number of subjects: 10
Study 37166798 — intervention group
Group type: EXPERIMENTAL
Intervention: Adverse events (AEs) monitoring
Number of subjects: 10
Study 37166817 — intervention group
Group type: EXPERIMENTAL
Intervention: Endocrine Therapy (ET) plus trastuzumab and pertuzumab
Number of subjects: 207
Study 37166817 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel plus trastuzumab and pertuzumab
Number of subjects: 207
Study 37166851 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited PCIT
Number of subjects: 144
Study 37166851 — intervention group
Group type: EXPERIMENTAL
Intervention: Time-limited CPP
Number of subjects: 144
Study 37166948 — intervention group
Group type: EXPERIMENTAL
Intervention: Memantine as an augmentative agent to a selective serotonin reuptake inhibitor
Number of subjects: 0
Study 37166948 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37166961 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low-Carbohydrate (VLC) diet intervention
Number of subjects: 112
Study 37166961 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily dietary self-monitoring
Number of subjects: 112
Study 37166961 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly dietary self-monitoring
Number of subjects: 112
Study 37166961 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindful eating
Number of subjects: 112
Study 37166961 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive affect skills training
Number of subjects: 112
Study 37166980 — intervention group
Group type: EXPERIMENTAL
Intervention: FED (participants ate breakfast and lunch)
Number of subjects: 12
Study 37166980 — intervention group
Group type: COMPARATOR
Intervention: FAST (participants remained fasted)
Number of subjects: 12
Study 37166995 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-calorie diet (LCD) with progressive weight loss (6%, 11%, 16%) in people without diabetes
Number of subjects: 0
Study 37166995 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic adjustable gastric banding (LAGB) in people without diabetes
Number of subjects: 0
Study 37166995 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) in people without diabetes
Number of subjects: 0
Study 37166995 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB) or low-calorie diet (LCD) in people with diabetes
Number of subjects: 0
Study 37166997 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-molecule activator of PP2A (SMAP, DT-061)
Number of subjects: 0
Study 37167078 — intervention group
Group type: EXPERIMENTAL
Intervention: Micro-osteoperforations (MOP)
Number of subjects: 28
Study 37167078 — intervention group
Group type: COMPARATOR
Intervention: Control (no MOP)
Number of subjects: 28
Study 37167165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ergoferon (1 tablet, 2 times a day for 3 weeks)
Number of subjects: 1057
Study 37167165 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1057
Study 37167303 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating miRNAs profiles according to the coronary pattern of the vascular compartment affectation.
Number of subjects: 100
Study 37167303 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetylcholine test for patients with isolated microvascular affectation or normal indexes.
Number of subjects: 100
Study 37167616 — intervention group
Group type: EXPERIMENTAL
Intervention: Train the Brain programme (motor/cognitive intervention)
Number of subjects: 0
Study 37167616 — intervention group
Group type: COMPARATOR
Intervention: Non-trained MCI controls
Number of subjects: 0
Study 37167764 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab plus relatlimab (NIVO + RELA; 480 mg and 160 mg, respectively)
Number of subjects: 0
Study 37167764 — intervention group
Group type: COMPARATOR
Intervention: Nivolumab (NIVO; 480 mg)
Number of subjects: 0
Study 37167775 — intervention group
Group type: EXPERIMENTAL
Intervention: MACE (Major Adverse Cardiovascular Events)
Number of subjects: 49479
Study 37167775 — intervention group
Group type: EXPERIMENTAL
Intervention: MACE
Number of subjects: 49479
Study 37167996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir, emtricitabine, and tenofovir alafenamide
Number of subjects: 643
Study 37167996 — intervention group
Group type: EXPERIMENTAL
Intervention: Dolutegravir, emtricitabine, and tenofovir disoproxil fumarate
Number of subjects: 643
Study 37167996 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz, emtricitabine, and tenofovir disoproxil fumarate
Number of subjects: 643
Study 37167996 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined dolutegravir groups
Number of subjects: 643
Study 37167996 — intervention group
Group type: COMPARATOR
Intervention: Efavirenz-containing group
Number of subjects: 643
Study 37168386 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision aid for organized cancer screening
Number of subjects: 75000
Study 37168386 — intervention group
Group type: COMPARATOR
Intervention: Standard organized cancer screening
Number of subjects: 75000
Study 37168472 — intervention group
Group type: EXPERIMENTAL
Intervention: Rectal swabs and molecular diagnostic tests for detection of enteropathogens
Number of subjects: 0
Study 37168686 — intervention group
Group type: EXPERIMENTAL
Intervention: Central blood pressure target (< 130 mm Hg)
Number of subjects: 116
Study 37168686 — intervention group
Group type: COMPARATOR
Intervention: Brachial blood pressure target (< 130 mm Hg)
Number of subjects: 116
Study 37169219 — intervention group
Group type: EXPERIMENTAL
Intervention: Text messaging about diabetes prevention
Number of subjects: 656
Study 37169219 — intervention group
Group type: EXPERIMENTAL
Intervention: Prediabetes decision aid
Number of subjects: 656
Study 37169219 — intervention group
Group type: EXPERIMENTAL
Intervention: Both text messaging and prediabetes decision aid
Number of subjects: 656
Study 37169219 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 656
Study 37169336 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial laparotomy
Number of subjects: 382
Study 37169336 — intervention group
Group type: COMPARATOR
Intervention: Peritoneal drain
Number of subjects: 382
Study 37169336 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized infants
Number of subjects: 382
Study 37169336 — intervention group
Group type: COMPARATOR
Intervention: Target population
Number of subjects: 382
Study 37169401 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 4 weeks
Number of subjects: 130
Study 37169401 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP treatment for 24 months
Number of subjects: 130
Study 37169489 — intervention group
Group type: EXPERIMENTAL
Intervention: Quincke needle
Number of subjects: 230
Study 37169489 — intervention group
Group type: EXPERIMENTAL
Intervention: Tuohy needle
Number of subjects: 230
Study 37169489 — intervention group
Group type: COMPARATOR
Intervention: Overall incidence
Number of subjects: 230
Study 37169489 — intervention group
Group type: COMPARATOR
Intervention: Bony contact during procedure
Number of subjects: 230
Study 37169498 — intervention group
Group type: EXPERIMENTAL
Intervention: Procalcitonin point-of-care testing
Number of subjects: 12
Study 37169498 — intervention group
Group type: EXPERIMENTAL
Intervention: Lung ultrasonography
Number of subjects: 12
Study 37169499 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine treatments for MG
Number of subjects: 1693
Study 37169499 — intervention group
Group type: EXPERIMENTAL
Intervention: Side effects from treatments
Number of subjects: 1693
Study 37169499 — intervention group
Group type: EXPERIMENTAL
Intervention: Comorbidities
Number of subjects: 1693
Study 37169499 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital Anxiety and Depression Scale
Number of subjects: 1693
Study 37169499 — intervention group
Group type: EXPERIMENTAL
Intervention: Work or study impact
Number of subjects: 1693
Study 37169504 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity interval training (HIIT) intervention, 3 sessions per week for 12 weeks on an ergometer bicycle.
Number of subjects: 80
Study 37169504 — intervention group
Group type: COMPARATOR
Intervention: No exercise control group (part of the 1:1 allocation).
Number of subjects: 80
Study 37169579 — intervention group
Group type: EXPERIMENTAL
Intervention: Hyper high haemoglobin content in red blood cells (Hyper-He) >49 pg
Number of subjects: 62
Study 37169708 — intervention group
Group type: EXPERIMENTAL
Intervention: Emotion Focused Mindfulness Therapy (EFMT) group delivered by Zoom
Number of subjects: 48
Study 37169708 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 48
Study 37169780 — intervention group
Group type: EXPERIMENTAL
Intervention: Brain serotonin 4 receptor binding
Number of subjects: 0
Study 37169780 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study 37169835 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab with IVIG
Number of subjects: 46
Study 37169835 — intervention group
Group type: COMPARATOR
Intervention: Rituximab
Number of subjects: 46
Study 37169992 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipidomic measures (904 lipid species and 252 fatty acids)
Number of subjects: 706
Study 37170018 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine Discharge Plan (RDP)
Number of subjects: 802
Study 37170018 — intervention group
Group type: COMPARATOR
Intervention: On-Demand Discharge Planning (DDP)
Number of subjects: 802
Study 37170043 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal dexmedetomidine
Number of subjects: 21
Study 37170043 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous opioids
Number of subjects: 21
Study 37170057 — intervention group
Group type: EXPERIMENTAL
Intervention: TMB-001 0.05%
Number of subjects: 33
Study 37170057 — intervention group
Group type: EXPERIMENTAL
Intervention: TMB-001 0.1%
Number of subjects: 33
Study 37170057 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 33
Study 37170109 — intervention group
Group type: EXPERIMENTAL
Intervention: Mifepristone (1200 mg/day)
Number of subjects: 158
Study 37170109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 158
Study 37170123 — intervention group
Group type: EXPERIMENTAL
Intervention: Open abdomen (OA) management with negative peritoneal pressure therapy (NPPT) dressing
Number of subjects: 0
Study 37170123 — intervention group
Group type: COMPARATOR
Intervention: Formal closure of the fascia
Number of subjects: 0
Study 37170159 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmed flexor-extensor alternating electrical acupoint stimulation (PES)
Number of subjects: 0
Study 37170159 — intervention group
Group type: COMPARATOR
Intervention: Conventional flexor-extensor alternating electrical acupoint stimulation (CES)
Number of subjects: 0
Study 37170191 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose polyethylene glycol 3350 (PEG, 459 g) and Gatorade (1.5 times the standard-dose)
Number of subjects: 69
Study 37170191 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose polyethylene glycol 3350 (PEG, 612 g) and Gatorade (2.0 times the standard-dose)
Number of subjects: 69
Study 37170191 — intervention group
Group type: COMPARATOR
Intervention: Standard doses of PEG (306 g to 357 g) and Gatorade
Number of subjects: 69
Study 37170191 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose preparations
Number of subjects: 69
Study 37170232 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-enhanced echocardiography using 59 echocardiographic features in a gradient-boosting classifier.
Number of subjects: 818
Study 37170232 — intervention group
Group type: EXPERIMENTAL
Intervention: Machine learning-enhanced echocardiography.
Number of subjects: 818
Study 37170260 — intervention group
Group type: EXPERIMENTAL
Intervention: High concentration sodium bicarbonate dentifrice
Number of subjects: 20
Study 37170260 — intervention group
Group type: COMPARATOR
Intervention: Control dentifrice
Number of subjects: 20
Study 37170284 — intervention group
Group type: EXPERIMENTAL
Intervention: Envarsus®
Number of subjects: 268
Study 37170284 — intervention group
Group type: COMPARATOR
Intervention: Advagraf™
Number of subjects: 268
Study 37170307 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant intravesical instillations of the drug selected based on drug screens in patient derived organoids (PDO) - Epirubicin, Mitomycin C, Gemcitabine, or Docetaxel for 6 instillations once weekly.
Number of subjects: 0
Study 37170307 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 37170329 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-system-embedded deprescribing intervention (educational brochure and self-care handouts, decision support for providers)
Number of subjects: 18
Study 37170329 — intervention group
Group type: COMPARATOR
Intervention: Usual care clinics
Number of subjects: 18
Study 37170385 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart rate-controlled walking training 5 times a week for 45 minutes
Number of subjects: 0
Study 37170385 — intervention group
Group type: COMPARATOR
Intervention: Usual standard of care (control group)
Number of subjects: 0
Study 37170480 — intervention group
Group type: EXPERIMENTAL
Intervention: mCIMT with real rTMS
Number of subjects: 46
Study 37170480 — intervention group
Group type: COMPARATOR
Intervention: mCIMT with sham rTMS
Number of subjects: 46
Study 37170709 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 μg IFS
Number of subjects: 40
Study 37170709 — intervention group
Group type: COMPARATOR
Intervention: 5 mg OM
Number of subjects: 40
Study 37170711 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2i
Number of subjects: 1700
Study 37170806 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive blood pressure control
Number of subjects: 7678
Study 37170806 — intervention group
Group type: COMPARATOR
Intervention: Standard blood pressure control
Number of subjects: 7678
Study 37170812 — intervention group
Group type: EXPERIMENTAL
Intervention: Electrophysiological studies (EPS) with programmed ventricular stimulation
Number of subjects: 120
Study 37170812 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeat EPS after PVR
Number of subjects: 120
Study 37170812 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up after PVR
Number of subjects: 120
Study 37170814 — intervention group
Group type: EXPERIMENTAL
Intervention: High sFlt-1/PlGF Ratio
Number of subjects: 0
Study 37170833 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowest MEEi tertile (MEEi<0.031 mL/s/g)
Number of subjects: 78
Study 37170833 — intervention group
Group type: COMPARATOR
Intervention: Merged second and third tertiles (MEEi≥0.031)
Number of subjects: 78
Study 37170950 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month structured, individualized and supervised exercise intervention
Number of subjects: 1
Study 37171081 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal oxytocin
Number of subjects: 0
Study 37171081 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral oxytocin
Number of subjects: 0
Study 37171081 — intervention group
Group type: COMPARATOR
Intervention: Control (medium pressure touch)
Number of subjects: 0
Study 37171121 — intervention group
Group type: EXPERIMENTAL
Intervention: HEK293T generated AAV vectors (serotype 8, 9, and rh.10)
Number of subjects: 0
Study 37171122 — intervention group
Group type: EXPERIMENTAL
Intervention: Videolaryngoscopy
Number of subjects: 759
Study 37171199 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibition for 2 weeks
Number of subjects: 0
Study 37171199 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibition for 12 weeks
Number of subjects: 0
Study 37171199 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 37171467 — intervention group
Group type: EXPERIMENTAL
Intervention: CamAPS FX hybrid closed loop (CL) system
Number of subjects: 35
Study 37171467 — intervention group
Group type: COMPARATOR
Intervention: Sensor-augmented pump (SAP)
Number of subjects: 35
Study 37171597 — intervention group
Group type: EXPERIMENTAL
Intervention: Tafasitamab+lenalidomide
Number of subjects: 3454
Study 37171602 — intervention group
Group type: EXPERIMENTAL
Intervention: Femtosecond laser-assisted minimally invasive lamellar keratoplasty (FL-MILK)
Number of subjects: 56
Study 37171620 — intervention group
Group type: EXPERIMENTAL
Intervention: Rituximab, bendamustine, and low-dose cytarabine (R-BAC)
Number of subjects: 57
Study 37171634 — intervention group
Group type: EXPERIMENTAL
Intervention: Radioactive iodine therapy (RAI)
Number of subjects: 21
Study 37171721 — intervention group
Group type: EXPERIMENTAL
Intervention: Talazoparib (oral, 1 mg once daily)
Number of subjects: 15
Study 37171752 — intervention group
Group type: EXPERIMENTAL
Intervention: Apremilast
Number of subjects: 180
Study 37171819 — intervention group
Group type: EXPERIMENTAL
Intervention: Engagement-focused care coordination (EFCC)
Number of subjects: 230
Study 37171819 — intervention group
Group type: COMPARATOR
Intervention: Problem-solving education (PSE)
Number of subjects: 230
Study 37171851 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intervention including real-time and web-based training, tobacco smoking treatment protocol, expert consultation, coaching, and organizational strategy meetings.
Number of subjects: 50
Study 37171851 — intervention group
Group type: EXPERIMENTAL
Intervention: Implementation intervention
Number of subjects: 50
Study 37171856 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR notification
Number of subjects: 2877
Study 37171856 — intervention group
Group type: COMPARATOR
Intervention: EHR notification (more than 5 notifications)
Number of subjects: 2877
Study 37171856 — intervention group
Group type: EXPERIMENTAL
Intervention: Provider survey
Number of subjects: 2877
Study 37171869 — intervention group
Group type: EXPERIMENTAL
Intervention: FT-EMDR
Number of subjects: 90
Study 37171869 — intervention group
Group type: COMPARATOR
Intervention: S-EMDR
Number of subjects: 90
Study 37171965 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (amox/clav) administered for 10 days
Number of subjects: 796
Study 37171965 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 796
Study 37171965 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (amox/clav) administered for 5 days
Number of subjects: 796
Study 37171989 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 200
Study 37171989 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex
Number of subjects: 200
Study 37171989 — intervention group
Group type: EXPERIMENTAL
Intervention: Spontaneous recovery
Number of subjects: 200
Study 37171989 — intervention group
Group type: COMPARATOR
Intervention: Cost analysis
Number of subjects: 200
Study 37171994 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pressure application via Multi-Pressure Dial (MPD) system
Number of subjects: 58
Study 37171994 — intervention group
Group type: COMPARATOR
Intervention: Control (fellow eye)
Number of subjects: 58
Study 37172100 — intervention group
Group type: EXPERIMENTAL
Intervention: IMA101 treatment (T-cell infusion and low-dose IL2)
Number of subjects: 14
Study 37172100 — intervention group
Group type: COMPARATOR
Intervention: Atezolizumab (Cohort 2)
Number of subjects: 14
Study 37172109 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction and cast immobilization
Number of subjects: 438
Study 37172109 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 438
Study 37172116 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive treatment (SBP target, 110 to <130 mmHg)
Number of subjects: 8511
Study 37172116 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (SBP target, 130 to <150 mmHg)
Number of subjects: 8511
Study 37172125 — intervention group
Group type: COMPARATOR
Intervention: Telehealth group
Number of subjects: 66
Study 37172125 — intervention group
Group type: COMPARATOR
Intervention: Hybrid group
Number of subjects: 66
Study 37172125 — intervention group
Group type: EXPERIMENTAL
Intervention: In-person group
Number of subjects: 66
Study 37172200 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadrivalent meningococcal conjugate vaccine (one dose)
Number of subjects: 102
Study 37172204 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemoimmunotherapy (CIT)
Number of subjects: 926
Study 37172204 — intervention group
Group type: EXPERIMENTAL
Intervention: Venetoclax-based therapies
Number of subjects: 926
Study 37172204 — intervention group
Group type: COMPARATOR
Intervention: CIT
Number of subjects: 926
Study 37172204 — intervention group
Group type: COMPARATOR
Intervention: Venetoclax-based treatments
Number of subjects: 926
Study 37172214 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulated residual OCT-μQFR
Number of subjects: 74
Study 37172214 — intervention group
Group type: EXPERIMENTAL
Intervention: Actual post-PCI OCT-μQFR
Number of subjects: 74
Study 37172783 — intervention group
Group type: EXPERIMENTAL
Intervention: Various types of drug delivery systems (including anti-VEGF drugs)
Number of subjects: 0
Study 37172783 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative drug delivery systems
Number of subjects: 0
Study 37172782 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel treatments for uveitis (specific interventions not detailed in the abstract)
Number of subjects: 0
Study 37172782 — intervention group
Group type: EXPERIMENTAL
Intervention: Current treatments involving immunosuppressive and anti-inflammatory medications
Number of subjects: 0
Study 37172884 — intervention group
Group type: EXPERIMENTAL
Intervention: AAV8-hCARp.hCNGB3
Number of subjects: 23
Study 37172934 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 W power with automatic fiber traction speed of 0.7 mm/s (LEED, 71.4 J/cm)
Number of subjects: 203
Study 37172934 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 W power with automatic fiber traction speed of 1.0 mm/s (LEED, 70 J/cm)
Number of subjects: 203
Study 37172934 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 W power with automatic fiber traction speed of 1.5 mm/s (LEED, 66.7 J/cm)
Number of subjects: 203
Study 37172934 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain intensity along the target vein
Number of subjects: 203
Study 37172934 — intervention group
Group type: EXPERIMENTAL
Intervention: Necessity for analgesics
Number of subjects: 203